Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.
about
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerAcquired resistance to EGFR-targeted therapies in colorectal cancerBiomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceKRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyKRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.The role of conserved waters in conformational transitions of Q61H K-ras.Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility studyThe landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemiasIntegrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomasCanDrA: cancer-specific driver missense mutation annotation with optimized features.Expanded RAS: refining the patient populationPyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally.Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation.Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysisrs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese populationSomatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site.Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexityImpact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation.Molecular Testing for Gastrointestinal Cancer.KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.Vibrational spectroscopy of biofluids for disease screening or diagnosis: translation from the laboratory to a clinical setting.Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.
P2860
Q24604601-B905A2DC-1F53-4437-8D62-D88234E0AECCQ24629474-E9A2C405-23FC-4FEF-A2CE-E60343897DB0Q26748924-4A49BEE0-BEDC-4701-9CBA-1C2BEAA6E04CQ26749012-5C57712D-2289-45C6-8412-6A479A638E4CQ27022741-2F522C7B-EDEB-40CD-BCD1-A7649BE9F652Q27852062-905E9541-95F9-4859-984A-822B41A1AA19Q28071772-E589FE14-CBD7-4AD2-8C49-E80E4A87B234Q28285473-102045E6-73B4-4A2F-8782-E752F15E01AAQ33693309-508F2EBE-45AB-4B74-90A1-677EE3E85BC1Q33732199-12AE9F6E-D960-42A1-83DC-A4E58249B47CQ34167863-DC835801-C983-47EA-AF12-57026DE4219BQ34340218-DA78C3FB-24A0-4493-87A3-EDE274191AA8Q34426265-725F873A-2862-469A-B611-A293DCC14032Q34465221-C26DEF33-BF2C-41EF-9CB3-29A642E7E55CQ35008028-F824E103-4BE1-43FB-BC83-90FE8D798161Q35035823-6204ACD1-F36A-4858-944E-243B79BBA2DBQ35102475-E446BA07-3615-48E9-A7CB-260EF93218C0Q35125613-4025775F-932E-480E-B08C-7E9449F99507Q35133788-51595BBB-C7D2-420A-AB42-3EBF5B3F104FQ35674250-75636F89-CA9D-4ECA-9BE6-1EEEB85797E9Q35677921-0BB8C321-E650-43DD-A3AB-62BA14415547Q35683647-74385C0A-4B44-4929-A763-0A5796C9D0EAQ35800764-650995C4-A465-455B-9A01-8FF09AD75D8EQ36038664-DC2B4C9B-D062-468E-A854-8621EF404989Q36177848-036B3A4D-7B8C-4916-9BC4-D9E2183EF656Q36212703-CFFEB5D4-0F6C-4B9D-9EBC-49D83D743BA6Q36293540-582DFD44-F857-43D8-A500-2245AA49335FQ36323471-33C8D402-8E69-4831-BD8C-E58D9C57AC28Q36918993-941FB221-2FB7-483D-95ED-F70284DD3F4EQ37581999-0AE2161F-C146-4E0E-A63B-9CEE75E5D3E7Q37710556-8C736E3B-3DFD-4BB6-A251-482596C03E8BQ38136134-F822FF0A-D541-4DF3-87BB-9B6A6B1BEA63Q38197570-BC72AA07-BA8A-46FB-AD68-DC67C87B1829Q38222512-838A1DCF-7046-41CB-A4C7-89BD36DA95B8Q38582586-73DC54B4-B1C7-4D42-883C-0D749C6BFD3FQ39010468-B28D86D5-72C5-408B-8B26-9E6A14B51F9EQ39038413-58346A59-BCCB-406B-80ED-2EDA11104DE9Q39139086-006760EE-B67D-40BA-96F1-825884F49DFFQ39182541-4DF78C7E-0A21-4078-A1A5-5CB2225C863AQ39628198-07B84915-792E-47AD-9829-5EA47D47EBF9
P2860
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Activating K-Ras mutations out ...... personalised cancer medicine.
@ast
Activating K-Ras mutations out ...... personalised cancer medicine.
@en
type
label
Activating K-Ras mutations out ...... personalised cancer medicine.
@ast
Activating K-Ras mutations out ...... personalised cancer medicine.
@en
prefLabel
Activating K-Ras mutations out ...... personalised cancer medicine.
@ast
Activating K-Ras mutations out ...... personalised cancer medicine.
@en
P2093
P2860
P356
P1476
Activating K-Ras mutations out ...... personalised cancer medicine.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605534
P407
P577
2010-02-01T00:00:00Z
P5875
P6179
1046556409